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Self-assembly of Ni-NTA-modified β-Annulus Peptides into 
Artificial Viral Capsids and Encapsulation of His-tagged Proteins 
Kazunori Matsuura,*a Tomohiro Nakamura,b Kenta Watanabe,b Takanori Noguchi,b Kosuke 
Minamihata,b Noriho Kamiya,b,c and Nobuo Kimizukab,d 
β-Annulus peptide bearing Cys at the N-terminal from tomato bushy stunt virus was synthesised using a standard Fmoc-
protected solid-phase method, and the petide was modified with Ni-NTA at the N-terminal. The  Ni-NTA-modified β-
annulus peptide self-assembled into virus-like nanocapsules of approximately 40 nm in diameter. The critical aggregation 
concentration of these nanocapsules in 10 mM Tris-HCl buffer (pH 7.3) at 25°C was 0.053 µM, which is 470 times lower 
than that of unmodified β-annulus peptides. Moreover, size exclusion chromatography of the peptide assembly indicated 
encapsulation of His-tagged green fluorescent protein in the Ni-NTA-modified artificial viral capsid. 
Introduction 
Viral capsids with rod-like or spherical morphology are 
exemplary natural supramolecular assemblies with discrete 
aggregation numbers and have been used as nanocontainers 
for inorganic materials, drugs and proteins.1 In particular, the 
encapsulation of proteins into spherical viral capsids has 
potential for developing novel drug delivery systems and 
enzymatic nanoreactors.2-4 Accordingly, Cornelissen and co-
workers encapsulated horse radish peroxidase and green 
fluorescence protein (GFP) into the recombinant cowpea 
chlorotic mottle virus (CCMV) capsid.2 Moreover, Hilvert and 
co-workers reported regarding the encapsulation of GFP into 
the virus-like capsid of lumazine synthase from Aquifex 
aeolicus.4 
Chemical strategies for rational designs of artificial peptide 
and protein assemblies have been progressively developed for 
constructing virus-like nanoarchitechtures.5-10 Specifically, 
Yeates and co-workers constructed discrete protein nanocages 
by self-assembly of fusion proteins possessing dimer- and 
trimer-forming subunits.7 Woolfson and co-workers also 
succeeded in constructing unilamellar spheres of 
approximately 100-nm size by self-assembly of two 
complementary coiled-coil hubs.8 We previously demonstrated 
that artificial C3-symmetric peptide conjugates self-assemble 
into virus-like nanospheres.11-13 However, it was difficult to 
encapsulate guest macromolecules into these nanospheres 
comprising of designed proteins or peptides because of the 
lack in methodology to selectively functionalize interior of the 
nanospheres. 
We recently demonstrated that the designed 24-mer β-
annulus peptide fragment INHVGGTGGAIMAPVAVTRQLVGS, 
which is found as a protein motif in tomato bushy stunt virus 
capsids, self-assembled into virus-like nanocapsules (artificial 
viral capsid) of 30–50 nm.14 The pH dependence of the ζ-
potential of artificial viral capsids suggests that the C-terminals 
of peptides are directed toward the outer surface while the N-
terminals are directed towards the interior.14b These 
properties enabled selective modification of artificial viral 
capsids surface with gold nanoparticles by C-terminal 
modification of the β-annulus peptide.14d In contrast, the N-
terminal-directed interior of nanocapsules might be cationic at 
neutral pH, enabling the encapsulation of DNA14b and anionic 
quantum dots14f inside the artificial viral capsids. In this study, 
we designed a novel β-annulus peptide modified with Ni-NTA 
(nitrilotriacetic acid) 1 at the N-terminal. Subsequently, we 
demonstrated the construction of an artificial viral capsid with 
internal Ni-NTA and showed its interaction with His-tagged 
GFP (Figure 1). 
Results and discussion 
A β-annulus peptide bearing Cys at the N-terminal 2 
(CINHVGGTGGAIMAPVA VTRQLVGS) was synthesised using a 
standard Fmoc-protected solid-phase method. Cys of peptide 2 
was reacted with maleimido-C3-NTA to obtain NTA-modified β-
annulus peptides. After purification using reverse-phase HPLC, 
Ni-NTA-modified β-annulus peptide 1 was prepared by mixing 
with equimolar NiCl2, and the identity of the peptide was 
confirmed using MALDI-TOF-MS (m/z = 2892.3 [M + H]+). 
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Fig. 1 Schematic of (a) the formation of Ni-NTA-modified artificial viral capsids by self-
assembly of Ni-NTA-modified β-annulus peptide 1, and (b) complexation of His-tagged 
EGFP with Ni-NTA-modified synthetic viral capsid. 
Self-assembly of Ni-NTA-modified β-annulus peptide 1 in 
10 mM Tris-HCl buffer (pH 7.3) was investigated using scanning 
electron microscopy (SEM), transmission electron microscopy 
(TEM), and dynamic light scattering (DLS). In SEM images, 
spherical assemblies of 25–40-nm diameters were abundantly 
observed (Figure 2A). TEM images stained with 
phosphotungstic acid also showed spherical assemblies of 
about 40-nm diameters (Figure 2B). The black centres of the 
structures in the TEM images might be caused by an 
accumulation of phosphotungstic acid in the interior of the 
spherical assemblies. Moreover, DLS analyses revealed 
average hydrodynamic diameters of 46.8 ± 10.5 nm (Figure 2C), 
which is comparable to the diameter of artificial viral capsids 
that self-assembled from unmodified 24-mer β-annulus 
peptide 3 (INHVGGTGGAIMAPVAVTRQLVGS).14a Therefore, 
modification of the β-annulus peptide with Ni-NTA at the N-
terminal minimally affected sizes and morphologies of the 
resulting capsids. The concentration dependence of Ni-NTA-
modified β-annulus peptide 3 scattering intensities indicates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 (A) SEM and (B) TEM images of aqueous solutions containing Ni-NTA-
modified β-annulus peptide 1 (0.1 mM) in 10 mM Tris-HCl buffer (pH 7.3) at 25°C. 
The SEM sample was coated with 3 nm Pt. The TEM sample was stained with 2% 
phosphotungstic acid. (C) Size distributions from dynamic light scattering (DLS) 
analyses of the aqueous solution. (D) Effects of Ni-NTA-modified β-annulus 
peptide 1 concentrations on the scattering intensity obtained from DLS in 10 mM 
Tris-HCl buffer (pH 7.3) at 25°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Raman spectra of NTA-modified β-annulus peptide (red) and Ni-NTA-
modified β-annulus peptide 1 (blue) on silicon wafer (excitation wavelength: 532 
nm). 
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Fig. 4 Size exclusion chromatograph of (a) assemblies of Ni-NTA-modified β-
annulus peptide 1 (detected at 220 nm); (b) His-tagged EGFP alone was detected 
at 488 nm; (c) Equimolar mixtures of His-tagged EGFP and Ni-NTA-modified β-
annulus peptide 1 assemblies were detected at 488 nm; (d) Equimolar mixtures 
of His-tagged EGFP and assemblies of unmodified β-annulus peptide 3 were 
detected at 488 nm. 
that the critical aggregation concentration (CAC) in 10 mM 
Tris-HCl buffer (pH 7.3) at 25°C is 0.053 µM (Figure 2D), 
whereas that of unmodified β-annulus peptide 3 under the 
same conditions was 25 µM.14a,f These remarkable differences 
in CACs suggest that the artificial viral capsid that was self-
assembled from Ni-NTA-modified β-annulus peptide 1 was 
more stable than that from unmodified β-annulus peptide 3. 
Hence, artificial viral capsids comprising peptide 1 are 
seemingly stabilised by electrostatic interactions between 
negative charges of the Ni-NTA complex and N-terminal 
ammonium ions. In addition, Raman spectrum of the artificial 
viral capsids comprising peptide 1 showed a peak at 1283 cm-1 
that was assigned to Ni–His coordination (Figure 3),15 
suggesting stabilization of artificial viral capsids by crosslinking 
of Ni-NTA with His residues of different peptide chain. 
Size exclusion chromatography (SEC) of Ni-NTA-modified β-
annulus peptide 1 assemblies showed a single elution peak at 
7.52 min (Figure 4a), reflecting enhanced stability of the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Size distributions from DLS experiments with aqueous solutions of (A) His-tagged 
EGFP alone and (B) equimolar mixtures of His-tagged EGFP and peptide 1 assemblies in 
10 mM Tris-HCl buffer (pH 7.3) at 25°C; [His-tagged EGFP] = [1] = 0.1 mM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 CD spectra of peptide 1 assemblies in the absence (blue) and presence (red) of 
His-tagged EGFP of in 10 mM Tris-HCl buffer (pH 7.3) at 25°C; [His-tagged EGFP] = [1] = 
0.1 mM. 
artificial viral capsid. The apparent number average molecular 
weight of Ni-NTA-modified β-annulus peptide 1 assemblies 
was estimated as 185 kDa using calibration curve of protein 
standards (see Experimental section). The apparent 
aggregation number was then calculated by dividing the 
molecular weight of the assembly (185 kDa) by that of peptide 
1 (2928 Da), giving 63.1, which is close to the ideal aggregation 
number (60) for dodecahedral assembly of β-annulus peptide. 
In further experiments, we examined encapsulation of 
hexahistidine-tagged enhanced green fluorescent protein (His- 
tagged EGFP) into artificial viral capsids that were self-
assembled from peptide 1 using SEC. It is known that 
dissociation constant of complex between Ni-NTA and 
hexahistidine-tag is about 10-8 M.16 Briefly, aqueous solutions 
of His-tagged EGFP in Tris- HCl buffer were added to powdered 
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samples of peptide 1 to encapsulate EGFP within artificial viral 
capsids via the interaction between the His-tag and Ni-NTA. 
SEC of His-tagged EGFP alone showed one peak at 9.02 min 
(Figure 4b), whereas SEC of equimolar mixtures of His-tagged 
EGFP and the peptide 1 assembly showed two elution peaks at 
7.02 and 9.62 min (Figure 4c), reflecting 91% encapsulation of 
EGFP in the artificial viral capsids and 9% free EGFP, 
respectively. Since isoelectric point (pI) of EGFP is 5.6, His-
tagged EGFP possesses anionic charges on the surface. It is 
presumed that His- tagged EGFP was encapsulated into the 
peptide 1 assembly by not only specific interaction between 
His-tag and Ni-NTA, but also electrostatic interactions between 
anionic EGFP and cationic residues of artificial viral capsid. In 
contrast, SEC of equimolar mixtures of His-tagged EGFP and 
the unmodified β-annulus peptide 3 assembly showed that 
91% of EGFP remained free, and only 9% of EGFP was non-
specifically bound to the assembly (Figure 4d). The nonspecific 
binding will be caused by electrostatic interactions between 
EGFP and artificial viral capsid. 
In further DLS experiments, equimolar mixtures of His-
tagged EGFP and peptide 1 capsids had average diameters of 
50.0 ± 17.5 nm, suggesting that encapsulation of EGFP had 
only minimal effects on the size distribution (Figure 5). A 
circular dichroism (CD) spectrum of the peptide 1 assembly 
showed negative peaks at 198 nm and 290 nm (Figure 6, blue). 
Conversely, a CD spectrum of the peptide 1 in the presence of 
equimolar His-tagged EGFP showed negative peaks at 215 nm 
and 290 nm, and the spectrum is almost consistent with the 
superposition of CD spectra for the peptide 1 assembly and 
EGFP (Figure 6, red). These results indicate that most His-
tagged EGFP was encapsulated into Ni-NTA-modified artificial 
viral capsids with little change in size and conformation. Figure 
7 shows the effect of concentration of His-tagged EGFP on the 
encapsulation into Ni-NTA-modified artificial viral capsids at 
[peptide 1] = 0.1 mM. His-tagged EGFP at 0.01 mM were 
hardly encapsulated into capsids, and the concentration 
dependence gave sigmoidal curve which became saturated at 
0.1-0.15 mM (almost 1:1 ratio). In contrast, His-tagged EGFP 
were minimally bound to the unmodified β-annulus peptide 3 
(Figure 7, blue). These indicate that His-tagged EGFP would be 
cooperatively bound to Ni-NTA-modified artificial viral capsid 
without significant nonspecific binding. 
Conclusions 
We demonstrated that following N-terminal Ni-NTA 
modification, β-annulus peptides self-assembled into relatively 
stable artificial viral capsids of approximately 40 nm in size. 
Moreover, the present SEC analyses indicate that these 
artificial viral capsids efficiently encapsulate His-tagged EGFP. 
These data warrant further investigations on the controlled 
release of His-tagged EGFP, other protein drugs and enzymes 
in artificial viral capsids, which would provide novel platform 
for designing drug carriers and nano-reactors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 The effect of concentration of His-tagged EGFP on the encapsulation into Ni-NTA-
modified (red) and unmodified (blue) artificial viral capsids at [peptide] = 0.1 mM in 10 
mM Tris-HCl buffer (pH 7.3) at 25°C. 
Experimental section 
General  
Reagents were obtained from commercial sources and were 
used without further purification. Deionised water of high 
resistivity (>18 MΩ cm) was purified using a Millipore 
Purification System (Milli-Q water) and was used as a solvent 
for the present peptides. Reversed-phase HPLC was performed 
at ambient temperature using a Simadzu LC-6AD liquid 
chromatograph equipped with a UV/Vis detector (220 nm, 
Shimadzu SPD-10AVvp) and Inertsil ODS-3 (GL Science) 
columns (250 × 4.6 mm or 250 × 20 mm). MALDI-TOF mass 
spectra were obtained using an Autoflex III instrument (Bruker 
Daltonics) in linear/positive mode with α-cyano-4-hydroxy 
cinnamic acid (α-CHCA) as a matrix. CD spectra were taken at 
25°C in a 1.0-mm quartz cell using a JASCO J-820 
spectrophotometer equipped with a Peltier-type thermostatic 
cell holder. Laser Raman spectrometry in the solid state was 
performed using a JASCO NRS-3000 instrument. Recombinant 
enhanced green fluorescent protein with N-terminal His × 6 
tags (His-tagged EGFP, MW = 27 kDa) was expressed in an 
Escherichia coli expression system, was purified using Ni-NTA 
resin and was confirmed using SDS-PAGE. Sequences of N-
terminal His-tagged EGFP are shown in Figure 8. 
 
 
 
 
 
 
Fig. 8 Sequence of His-tagged EGFP. 
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Synthesis of Cys-β-annulus peptide (2). 
The peptide H-Cys(Trt)-Ile-Asn(Trt)-His(Trt)-Val-Gly-Gly-
Thr(tBu)-Ile-Met-Ala-Pro-Val-Ala-Val-Thr(tBu)-Arg(Mtr)-Gln 
(Trt)-Leu-Val-Gly-Ser(tBu)-Alko-PEG resin was synthesised on 
Fmoc-Ser(tBu)-Alko-PEG resin (476 mg, 0.21 mmol/g; 
Watanabe Chemical Ind. Ltd) using standard Fmoc-based 
FastMoc coupling chemistry (5 eq. Fmoc-amino acids) with an 
ABI 433A synthesizer (Applied Biosystems). A 
dimethylformamide solution containing 2-(1H-benzotriazole-1-
yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate (HBTU, 
0.5 M) and 1-hydroxybenzotriazole hydrate (HOBt•H2O, 0.5 
M) was used as a coupling reagent. Neutralization and Fmoc 
deprotection was achieved using 2.0-M diisopropylamine in 
NMP and 20% piperidine in N-methylpyrrolidone (NMP), 
respectively. Peptidyl-resins were washed with NMP and were 
then dried under a vacuum. Peptides were deprotected and 
cleaved from the resin by treatment with a cocktail of 
trifluoroacetic acid (TFA)/1, 2-ethanedithiol/triisopropylsilane 
/water = 9.4/2.5/2.5/1.0 (mL) at room temperature for 3 h. 
Reaction mixtures were filtered to remove resins, and filtrates 
were concentrated under a vacuum. Peptides were 
precipitated by adding ice-cooled methyl-tert-butyl ether 
(MTBE) to the residue, and supernatants were decanted. After 
washing five times with MTBE, precipitated peptides were 
dried under vacuum. Crude products were purified using 
reversed-phase HPLC (Inertsil ODS-3) and were eluted with a 
linear gradient of CH3CN/water (25/75 to 27/73 over 100 min) 
containing 0.1% TFA. Eluted fractions containing desired 
peptides were lyophilised to give flocculent solids. The isolated 
yield was 32 mg (14%); MALDI-TOF-MS (matrix: α-CHCA): m/z 
= 2408.0 ([M + H]+). 
Preparation of Ni-NTA-modified-β-annulus peptide (1). 
Cys-β-annulus peptide 2 in 0.5 mL of 0.5-mM aqueous solution 
was degassed by N2 bubbling and was mixed with 0.5 mL of a 
1.0-mM aqueous solution (degassed by N2 bubbling) of 
maleimido-C3-NTA (Dojindo Laboratories) at room 
temperature. After incubating for 12 h at room temperature, 
mixtures were purified using reversed-phase HPLC (Inertsil 
ODS-3) and were eluted with a linear gradient of 
acetonitrile/water (25/75 to 27/73 over 100 min) containing 
0.1% TFA to provide pure NTA-β-annulus peptide (isolated 
yield: 0.74 mg, 52%); MALDI-TOF-MS (matrix: α-CHCA): m/z = 
2835.1 ([M + H]+).  
NTA-β-annulus peptide (3.2 mg) were dissolved in 10-mM 
Tris-HCl buffer to prepare 5.6-mM aqueous solutions. 
Subsequently, 50-mM aliquots of NiCl2 solution in 10-mM Tris-
HCl buffer were added to peptide solutions to [peptide] and 
[Ni2+] of 5.0 mM. Ni-complex 1 formation was confirmed using 
MALDI-TOF-MS (matrix: α-CHCA): m/z = 2892.3 ([M + H]+). 
Dynamic Light Scattering.  
Stock solutions (1.0 mM) of Ni-NTA-β-annulus peptide 1 in 10-
mM Tris-HCl buffer were prepared by dissolving in buffer 
without sonication or heating. Samples were prepared by 
diluting stock solutions with 10-mM Tris-HCl buffer and were 
incubated at 25°C for 12 h before DLS measurements using a 
Zetasizer Nano ZS (MALVERN) instrument at 25°C with an 
incident He–Ne laser (633 nm). During measurements, count 
rates (sample scattering intensities) were also provided. 
Correlation times of scattered light intensities G(τ) were 
measured several times and means were calculated and fitted 
to equation 1, where B is baseline, A is amplitude, q is 
scattering vector, τ is delay time and D is the diffusion 
coefficient. 
G(τ) = B + A exp(−2q2Dτ )                   (1) 
Hydrodynamic radii (RH) of scattering particles were calculated 
using the Stokes–Einstein equation (eq. 2), where η is solvent 
viscosity, kB is Boltzmann’s constant and T denotes the 
absolute temperature. 
 RH = kBT/6πηD                         (2) 
Scanning Electron Microscopy. 
DLS samples were observed using SEM. Briefly, 5 µL aliquots of 
DLS samples were applied to hydrophilised carbon-coated Cu-
grids (ALLANCE Biosystems) for 60 s and were then removed. 
Grids were then dried in vacuo, coated with platinum (ca. 3 nm, 
Hitachi E-1030 ion sputter) and then observed using SEM  
(Hitachi S-5000) with an acceleration voltage of 15 kV at a tilt 
angle of 30°. 
Transmission Electron Microscopy. 
5 µL aliquots of DLS samples were applied to hydrophilised 
carbon-coated Cu-grids (ALLANCE Biosystems) for 60 s and 
were then removed. A drop of 2 wt% aqueous sodium 
phosphotungstate was placed on each of the grids. After the 
sample-loaded carbon-coated grids were dried in vacuo, they 
were observed by TEM (JEOL JEM 1400 Plus) using an 
acceleration voltage of 80 kV. 
Size Exclusion Chromatography. 
SEC analyses of the assemblies of Ni-NTA-modified β-annulus 
peptide 1 (0.1 mM), His-tagged EGFP (0.1 mM) and their 
equimolar mixture after elution with 10 mM Tris-HCl buffer 
(pH 7.3) were performed at 25°C using a Shimadzu LC-6AD 
liquid chromatograph equipped with a UV/Vis detector 
(Shimadzu SPD-10AVvp) and a TSKgel G3000SWXL (TOSOH 
Bioscience, 300 × 7.8 mm ID). SEC of peptide 1 was monitored 
at 220 nm, whereas those of His-tagged EGFP and the mixture 
were monitored at 488 nm. Calibration curve (Figure 7) was 
prepared using thyroglobulin (669 kDa), γ-globulin (160 kDa), 
ribonuclease A (137 kDa) and p-aminobenzoic acid (137 Da) as 
molecular weight standards. Nonlinear curve fitting of 
calibration curve indicated that the relationship between the 
logarithm of molecular weight and elution volume (x/mL) 
could be expressed as follows: 
log Mn = 0.0022x3 − 0.0702x2 + 0.2588x + 6.1545       (3) 
Apparent average molecular weights of assemblies of Ni-NTA-
modified β-annulus peptide 1 were estimated from calibration 
curve using equation 3. 
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Fig.9 Calibration curve for SEC analyses; Thyroglobulin (669 kDa), γ-globulin (160 kDa), 
ribonuclease A (137 kDa) and p-aminobenzoic acid (137 Da) were used as molecular 
weight standards. 
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